Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.
Drugmakers renew interest in antibiotic development
Using a med-tech strategy may help stem concern about CAR T-cell technology’s complicated distribution and anticipated high prices, said Novartis exec.
Reframing the Debate: Why Drug Spending Can Lower Costs
Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
Do We Need Formal Surveys Anymore?
April 22, 2016
8:27 pm
“Social can enable a better starting point to yield better questions and thus make surveys less in number yet greater in value.”
Intouch Solutions’ Weissberg on the rising payer voice
With a lead role in IBM Watson’s bold gambit to transform healthcare, Kathy McGroddy-Goetz ranks as one of the enterprise’s most important individuals.
Guidemark Health’s Fascetti on Ads that Change Behavior